Bausch + Lomb

Daniel M. Wechsler has been appointed corporate vice president and global president of Bausch + Lomb’s Pharmaceuticals business. Mr. Wechsler assumes the role from Brent Saunders, who has been serving as interim global president of the business unit for the past several months.

“Dan has a strong track record as a senior executive driving high performance in global health care companies,” said Brent Saunders, B+L’s chief executive officer. “His recruitment reflects our continuing progress toward transforming B+L into a high-performance competitor.”

Mr. Wechsler most recently served as head of U.S. Strategy, Commercial Model Innovation and Business Development for Merck, a role he was appointed to following the company’s acquisition of Schering-Plough in 2009. While at Schering-Plough, he was group vice president, Global Business Operations and Selling Excellence, and a member of the global management team. In 2003, Mr. Wechsler joined Pfizer as vice president for its U.S. Specialty Sales organization. He began his career in 1991 with The Upjohn Company (later Pharmacia Corporation), holding a variety of positions.